" class="no-js "lang="en-US"> RemedyBio - Medtech Alert
Saturday, September 30, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
RemedyBio | Pharmtech Focus

RemedyBio

About RemedyBio

RemedyBio

Based in Dublin, RemedyBio is a nano scale biotechnology company pioneering ultra high throughput therapeutic and diagnostic discovery. The company’s discovery technology massively improves the speed and scale of single cell analysis, with next-generation applications in immuno-oncology, autoimmune disease, and infectious disease.

Related Story

Appointments

 RemedyBio Introduces Scientific Advisory Board | Pharmtech Focus

RemedyBio Introduces Scientific Advisory Board

May 26 2022

RemedyBio, a biotech company pioneering its proprietary ultra-high throughput single cell Nanoreactor™ platform for discovery […]

COVID-19

 RemedyBio Completes €10.5M Financing from European Innovation Council | Pharmtech Focus

RemedyBio Completes €10.5M Financing from European Innovation Council

July 20 2021

RemedyBio, an immunology focused discovery and development company, today announces the final closing of an […]